A major moment in India’s fight against type-2 diabetes arrived this week with the launch of Ozempic, the globally popular semaglutide drug known for its strong effects on blood sugar control and ...
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming ...
Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly. Novo Nordisk also lost a bidding war for a promising start-up. Novo Nordisk ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in the weight-loss-drug market. U.S.-listed shares fell over 5% on Monday to a ...
Hosted on MSN
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
Novo Nordisk has lost ground in the weight-loss drug market to Eli Lilly and telehealth companies. The company's new CEO is being far more aggressive, which bodes well. Novo's upcoming Wegovy pill is ...
A Novo Nordisk challenge has driven a Pennsylvania-based telehealth company to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against ...
Novo Nordisk announced Monday it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal with the Trump administration to drop prices for customers. The Wegovy 0.25 ...
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered ...
GLP-1 weight loss drugs are still far from cheap, but some of the prices keep dropping. Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and ...
Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback